



NASAL INNOVATION FORUM

DRAFT PROGRAM (as of 7/7/25) Timing, Presentation Titles, and Speakers Subject to Change.

IPAC-RS Nasal Innovation Forum

September 18-19, 2025 // In-Person Event

Trenton Country Club 201 Sullivan Way, West Trenton, NJ 08628

(See [website for logistical details](#))

Day 1 – Thursday, September 18 th 8:30 AM – 5 PM ET	
8:00 – 8:30 AM	Check In and Continental Breakfast
8:30 – 9:00 AM	Housekeeping and Rules of Engagement (by IPAC-RS) Welcoming and Forum Introduction
<i>Session 1: Scientific Understanding (Moderator: TBC)</i>	
9:00 – 9:30 AM	<i>Intranasal Nanovaccines for Tuberculosis Prevention: Novel Strategies in Formulation and Delivery</i> Sara Maloney, RTI International
9:30 – 10:00 AM	<i>Brain Bound! Nose-to-Brain Delivery with In-situ Intranasal Gels</i> Vivek Gupta, St John's University
10:00 – 10:30 AM	<i>Current and Future Nasal Pipeline: Benefits and Challenges in Drug Repurposing</i> Irene Rossi, Harro Hoefliger
10:30 – 11:00 AM	Coffee Break & Networking
<i>Session 2: Marrying Formulation and Device & the Role of Preclinical Models (Moderator: TBC)</i>	
11:00 – 11:30 AM	<i>Targeting Delivery, Angle of Administration, Positioning and Human Factor for Powder and Liquid Nasal Delivery</i> Reenal Gandhi, Aptar Pharma
11:30 – 12:00 PM	<i>How to Use Non-clinical Models in Intranasal Drug Development</i> Philip Kuehl, Lovelace Biomedical
12:00 – 12:30 PM	<i>Strategic Product Design for Liquid Nasal Formulations: A Target Profile Perspective</i> Lucas Silva, Nanopharm, An Aptar Pharma Company
12:30 – 1:30 PM	Lunch Break & Networking
1:30 – 2:00 PM	<i>Design of High-loading, Mucoadhesive Self-emulsifying Nasal Delivery Systems for Extended-release of BCS Classes II, III & IV Drugs</i> Deb Das, Bayer U.S. LLC

DRAFT PROGRAM (as of 7/7/25) Timing, Presentation Titles, and Speakers Subject to Change.

Day 1 – Thursday, September 18 th 8:30 AM – 5 PM ET	
2:00 - 2:30 PM	<i>Intranasal Nose to Brain Delivery of ST266 Amnion Cell Derived Secretome: Non-Human Primate to Clinical Translation</i> Larry Brown, Noveome Biotherapeutics, Inc.
2:30 – 3:00 PM	<i>Developing Nasal Powder Products: Formulation, Delivery and Characterization</i> Alan Watts, Catalent
3:00 – 3:30 PM	Coffee Break & Networking
3:30 – 4:00 PM	<i>Powder Nasal Spray Culmination Drug as Patient-Centric Rescue Medicine</i> Kay Olmstead, Nano PharmaSolutions, Inc.
4:00 – 4:30 PM	<i>Development of a Loxapine Nasal Powder: Leveraging a 505(b)(2) Regulatory Pathway and PK Bridging to Enable At-Home Prevention of Acute Agitation</i> Paul Shields, MOD3 Pharma
4:30 – 5:00 PM	Panel
5:00 – 6:30 PM	Happy Hour & Networking

Day 2 – Friday, September 19 th 8:30 AM – 1 PM ET	
8:00 – 8:30 AM	Check In and Continental Breakfast
8:30 – 9:00 AM	Welcoming and Forum Introduction
<i>Session 3: Good Practices for Manufacturing and Commercialization (Moderator: TBC)</i>	
9:00 – 9:30 AM	<i>Sniffing Out the Standards: Making Sense of Evolving Nasal Spray Testing Expectations</i> Maria Smith, Proveris
9:30 – 10:00 AM	<i>Industry Perspective</i> Mark Ignaczak, Catalent
10:00 – 10:30 AM	<i>Development and NDA Approval of Atzumi™ (Dihydroergotamine Nasal Powder)</i> Robert Schultz, Satsuma Pharmaceuticals, Inc.
10:30 – 11:00 AM	Coffee Break & Networking
<i>Session 4: Regulatory Perspective (Moderator: TBC)</i>	
11:00 – 11:30 AM	<i>Regulatory Perspectives on Nasal Products</i> FDA Speaker Invited
11:30 AM – 12:00 PM	<i>Industry Regulatory Perspective</i> Rachel Ward, Kymanox
12:00 – 12:30 PM	<i>Post-approval Changes and How to Handle Them</i> Prasad Peri, Eli Lilly Company
12:30 PM	Closing Remarks (by IPAC-RS and organizing companies)